The initial group of 1, 000 will participate in a series of baseline studies including cardiac function, testing for joint abnormalities and psychosocial tests.
Merck is conducting two other large tests of Vytorin as part of the joint venture, under which the companies split the development responsibilities and sales for Vytorin and Zetia.